Abstract
In recent years, an association between hypermobile Ehlers-Danlos syndrome (hEDS), mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS) has garnered attention and patients are increasingly presenting with this triad. However, a real relationship between these entities is unclear due to a lack of scientific validity. We conducted an extensive review of the literature using two different search strategies. A narrower strategy included 88 searches of various combinations of terms for each of the three conditions, yielding 19 unique papers. A broader search included 136 searches of various combinations of terms but included all forms of EDS and yielded 40 unique papers. Of these, only four and nine papers from the narrower and broader search strategies were original research articles. None of these papers resulted from a combination of the search terms for the three conditions. All three clinical entities are controversial in either existence or pathogenesis. MCAS is a poorly defined clinical entity, and many studies do not adhere to the proposed criteria when establishing the diagnosis. Patients previously diagnosed with EDS hypermobility type may not meet the new, stricter criteria for hEDS but may for a less severe hypermobility spectrum disorder (HSD). The pathophysiology of POTS is still unclear. An evidence-based, common pathophysiologic mechanism between any of the two, much less all three conditions, has yet to be described. Our review of the literature shows that current evidence is lacking on the existence of MCAS or hEDS as separate or significant clinical entities. Studies proposing a relationship between the three clinical entities are either biased or based on outdated criteria. The reason behind the purported association of these entities stems from an overlapping pool of vague, subjective symptoms, which is inadequate evidence to conclude that any such relationship exists.
Similar content being viewed by others
References
Beighton P, Grahame R, Bird H (2012) Introduction to hypermobility. In: Hypermobility of joints. Springer, p 1
Parapia LA, Jackson C (2008) Ehlers-Danlos syndrome – a historical review. Br J Haematol. 141(1):32–35
Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ (1999) Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Am J Med Genet. 77(1):31–37
Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J et al (2017) The 2017 International Classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):8–26
Steinmann B, Royce PM, Superti-Furga A (2003) The Ehlers-Danlos syndrome. In: Connective tissue and its heritable disorders. Wiley-Blackwell, pp 431–523
Tinkle B, Castori M, Berglund B, Cohen H, Grahame R, Kazkaz H et al (2017) Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 175(1):48–69
De Paepe A, Malfait F (2012) The Ehlers–Danlos syndrome, a disorder with many faces. Clin Genet. 82(1):1–11
Castori M, Camerota F, Celletti C, Grammatico P, Padua L (2010) Ehlers-Danlos syndrome hypermobility type and the excess of affected females: possible mechanisms and perspectives. Am J Med Genet A. 152A(9):2406–2408
Levy HP (2018) Ehlers-Danlos syndrome, hypermobility type. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K et al (eds) GeneReviews. University of Washington, Seattle, Seattle
Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M et al (2003) Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet. 73(1):214–217
Morissette R, Chen W, Perritt AF, Dreiling JL, Arai AE, Sachdev V et al (2015) Broadening the spectrum of Ehlers Danlos syndrome in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 100(8):1143
Narcisi P, Richards AJ, Ferguson SD, Pope FM (1994) A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. Hum Mol Genet. 3(9):1617–1620
Syx D, Symoens S, Steyaert W, De Paepe A, Coucke PJ, Malfait F (2015) Ehlers-Danlos syndrome, hypermobility type, is linked to chromosome 8p22-8p21.1 in an extended Belgian family. Dis Markers 2015:e828970
Castori M, Camerota F, Celletti C, Danese C, Santilli V, Saraceni VM et al (2010) Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A. 152A(3):556–564
Castori M, Dordoni C, Morlino S, Sperduti I, Ritelli M, Valiante M et al (2015) Spectrum of mucocutaneous manifestations in 277 patients with joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet C Semin Med Genet. 169C(1):43–53
Castori M, Morlino S, Celletti C, Ghibellini G, Bruschini M, Grammatico P et al (2013) Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type. Am J Med Genet A. 161(12):2989–3004
Castori M, Sperduti I, Celletti C, Camerota F, Grammatico P (2011) Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome, hypermobility type). Clin Exp Rheumatol. 29(6):998–1005
Castori M, Celletti C, Camerota F, Grammatico P (2011) Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. Clin Exp Rheumatol. 29(3):597–598
Maeland S, Assmus J, Berglund B (2011) Subjective health complaints in individuals with Ehlers-Danlos syndrome: a questionnaire study. Int J Nurs Stud. 48(6):720–724
Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q (2017) Gastrointestinal involvement in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):181–187
Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A (2017) A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 175(1):148–157
Beighton P, Solomon L, Soskolne C (1973) Articular mobility in an African population. Ann Rheum Dis. 32(5):413–418
Juul-Kristensen B, Schmedling K, Rombaut L, Lurd H, Engelbert RHH (2017) Measurement properties of clinical assessment methods for classifying generalized joint hypermobility—a systematic review. Am J Med Genet C Semin Med Genet. 175(1):116–147
Hakim AJ, Grahame R (2003) A simple questionnaire to detect hypermobility: an adjunct to the assessment of patients with diffuse musculoskeletal pain. Int J Clin Pract. 57(3):163–166
Chopra P, Tinkle B, Hamonet C, Brock I, Gompel A, Bulbena A et al (2017) Pain management in the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 175(1):212–219
Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Chronic fatigue in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174
Hakim A, O’Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P (2017) Cardiovascular autonomic dysfunction in Ehlers–Danlos syndrome—hypermobile type. Am J Med Genet C Semin Med Genet. 175(1):168–174
Bathen T, Hångmann AB, Hoff M, Andersen LØ, Rand-Hendriksen S (2013) Multidisciplinary treatment of disability in Ehlers-Danlos syndrome hypermobility type/hypermobility syndrome: a pilot study using a combination of physical and cognitive-behavioral therapy on 12 women. Am J Med Genet A. 161A(12):3005–3011
Raj SR (2006) The postural tachycardia syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 6(2):84–99
Schondorf R, Low PA (1993) Idiopathic postural orthostatic tachycardia syndrome. Neurology 43(1 Part 1):132–137
Wooley CF (1976) Where are the diseases of yesteryear? DaCosta’s syndrome, soldiers heart, the effort syndrome, neurocirculatory asthenia--and the mitral valve prolapse syndrome. Circulation. 53(5):749–751
Stewart J (2013) Common syndromes of orthostatic intolerance. Pediatrics. 131(5):968–980
Robertson D (1999) The epidemic of orthostatic tachycardia and orthostatic hypotension. Am J Med Sci. 319:75–77
Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G (2002) Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med. 137(9):753–763
Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;S1566–0702(18):30025–0.
Garland EM, Raj SR, Black BK, Harris PA, Robertson D (2007) The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 69:790–798
Thieben M, Sandroni P, Sletten D, Benrud-Larson L, Fealey R, Vernino S et al (2007) Postural orthostatic tachycardia syndrome: the Mayo Clinic experience. Mayo Clin Proc. 82(3):308–313
Arnold AC, Ng J, Raj SR (2018) Postural tachycardia syndrome – diagnosis, physiology, and prognosis. Auton Neurosci. S1566–0702(17):30354–30355
Smith JJ, Porth CM, Erickson M (1994) Hemodynamic response to the upright posture. J Clin Pharmacol. 34(5):375–386
Raj SR (2013) Postural tachycardia syndrome (POTS). Circulation. 127(23):2336
Bonyhay I, Freeman R (2004) Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation. 110(20):3193–3198
Haensch C, Tosch M, Katona I, Weis J, Isenmann S (2014) Small-fiber neuropathy with cardiac denervation in postural tachycardia syndrome. Muscle Nerve. 50(6):956–961
Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M et al (2000) The neuropathic postural tachycardia syndrome. N Eng J Med. 343(14):1008–1014
Sheldon R, Grubb B, Olshansky B, Shen W, Calkins H, Brignole M et al (2015) 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 12(6):e63
Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I et al (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 342(8):541–549
Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR et al (2001) Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci. 940:527–543
Marques FZ, Eikelis N, Bayles RG, Lambert EA, Straznicky NE, Hering D et al (2017) A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. Mol Psychiatry. 22(1):134–141
Bayles R, Harikrishnan KN, Lambert E, Baker EK, Agrotis A, Guo L et al (2012) Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler Thromb Vasc Biol. 32(8):1910–1916
Lambert E, Eikelis N, Esler M, Dawood T, Schlaich M, Bayles R et al (2008) Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 1(2):103–109
Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I et al (2002) Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation. 105(3):347–353
Green EA, Raj V, Shibao CA, Biaggioni I, Black BK, Dupont WD et al (2013) Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2(5):e000395
Raj SR, Biaggioni I, Yamhure PC, Black BK, Paranjape SY, Byrne DW et al (2005) Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation. 111(13):1574–1582
Parsaik A, Allison TG, Singer W, Sletten DM, Joyner MJ, Benarroch EE et al (2012) Deconditioning in patients with orthostatic intolerance. Neurology. 79(14):1435–1439
Nagiub M, Moskowitz W, Fortunato J (2018) Systematic literature review of pathophysiology of postural orthostatic tachycardia syndrome (angiotensin II receptor subtypes imbalance theory). Prog Pediatr Cardiol
Sandroni P, Opfer-Gehrking TL, McPhee BR, Low PA (1999) Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 74(11):1106–1110
Goodman B (2018) Evaluation of postural tachycardia syndrome (POTS). Auton Neurosci 18(18):30015–30018
Bagai K, Wakwe CI, Malow B, Black BK, Biaggioni I, Paranjape SY et al (2013) Estimation of sleep disturbances using wrist actigraphy in patients with postural tachycardia syndrome. Auton Neurosci. 177(2):260–265
Agarwal G, Ritch S (2007) Postural orthostatic tachycardia syndrome. Postgrad Med J. 83(981):478–480
Fu Q, Vangundy TB, Shibata S, Auchus RJ, Williams GH, Levine BD (2011) Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 58(2):167–175
Fu Q, Vangundy TB, Galbreath MM, Shibata S, Jain M, Hastings JL et al (2010) Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 55(25):2858–2868
Winker R, Barth A, Bidmon D, Ponocny I, Weber M, Mayr O et al (2005) Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension. 45(3):391–398
Sousa A, Lebreiro A, Freitas J, Maciel MJ (2012) Long-term follow-up of patients with postural tachycardia syndrome. Clin Auton Res. 22(3):151–153
Lai CC, Fischer PR, Brands CK, Fisher JL, Porter CJ, Driscoll SW et al (2009) Outcomes in adolescents with postural orthostatic tachycardia syndrome treated with midodrine and beta-blockers. Pacing Clin Electrophysiol. 32(2):234–238
Kimpinski K, Figueroa JJ, Singer W, Sletten DM, Iodice V, Sandroni P et al (2012) A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc. 87(8):746–752
Afrin LB (2013) Presentation, diagnosis, and management of mast cell activation syndrome. In: Murray DB (ed) Mast cells: phenotypic features, biological functions and role in immunity. Nova Science Publishers, Inc, pp 155–232
Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67(6):345–368
Metcalfe DD (1991) Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 96(3 Suppl):65S
Roberts LJ, Oates JA (1991) Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol. 96(3 Suppl):65S
Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 37(6):435–453
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 25(7):603–625
Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR et al (2007) Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. IAA. 142(2):158–164
Akin C, Valent P, Metcalfe DD (2010) Mast cell activation syndrome: proposed diagnostic criteria: towards a global classification for mast cell disorders. J Allergy Clin Immunol. 126(6):1099–1104
Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC et al (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157(3):215
Valent P, Akin C, Metcalfe DD (2017) Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 129(11):1420–1427
Brockow K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 34(2):283–295
Kettelhut BV, Metcalfe DD (1991) Pediatric mastocytosis. J Invest Dermatol. 96(3 Suppl):65S
Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al (1995) The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 96(6):2702–2710
Dahlin JS, Hallgren J (2015) Mast cell progenitors: origin, development and migration to tissues. Mol Immunol. 63(1):9–17
Silva EZ (2014) Marcelino da, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 62(10):698–738
Akin C (2017) Mast cell activation syndromes. J Allergy Clin Immunol. 140(2):349–355
Molderings GJ, Brettner S, Homann J, Afrin LB (2011) Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 4(1):10
Valent P (2013) Mast cell activation syndromes: definition and classification. Eur J Allergy Clin Immunol 68:417–424
Cardet J, Castells M, Hamilton M (2013) Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 13(1):10–18
Seneviratne S, Maitland A, Afrin L (2017) Mast cell disorders in Ehlers–Danlos syndrome. Am J Med Genet C Semin Med Genet. 175C(1):226–236
Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL et al (2016) Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg’s Arch Pharmacol 389:671
Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2(3):266–270
Garriga MM, Friedman MM, Metcalfe DD (1988) A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol. 82(3 Pt 1):425–432
Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P et al (2007) Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 110(7):2331–2333
Astle JM, Rose MG, Racke FK, Tormey CA, Siddon AJ (2017) R634W KIT mutation in an adult with systemic mastocytosis. Lab Med. 48(3):253–257
Pollard WL, Beachkofsky TM, Kobayashi TT (2015) Novel R634W c-kit mutation identified in familial mastocytosis. Pediatr Dermatol. 32(2):267–270
Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 103(8):3222–3225
Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A et al (2003) One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 162(3):737–746
Grahame R, Bird HA, Child A (2000) The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol. 27(7):1777–1779
Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Sillence D (2009) The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A. 149A(11):2368–2370
Castori M, Dordoni C, Valiante M, Sperduti I, Ritelli M, Morlino S et al (2014) Nosology and inheritance pattern(s) of joint hypermobility syndrome and Ehlers-Danlos syndrome, hypermobility type: a study of intrafamilial and interfamilial variability in 23 Italian pedigrees. Am J Med Genet A. 164(12):3010–3020
Rowe P, Barron D, Calkins H, Maumenee I, Tong PY, Geraghty MT (1999) Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr. 135(4):494–499
Grigoriou E, Boris JR, Dormans JP (2015) Postural Orthostatic Tachycardia Syndrome (POTS): association with Ehlers-Danlos syndrome and orthopaedic considerations. Clin Orthop Relat Res 473(2):722
Wallman D, Weinberg J, Hohler AD. Ehlers–Danlos syndrome and postural tachycardia syndrome: a relationship study. J Neurol Sci. 2014;340(1–2):99–102.
Gazit Y, Nahir AM, Grahame R, Jacob G (2003) Dysautonomia in the joint hypermobility syndrome. Am J Med. 115(1):33–40
Miglis M, Schultz B, Muppidi S (2017) Postural tachycardia in hypermobile Ehlers-Danlos syndrome: a distinct subtype? Auton Neurosci. 208:146–149
Shibao C, Jackson Roberts IIL, Raj S, Black B, Harris P, Biaggioni I (2005) Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 45(3):385–390
Doherty T, White A (2018) Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. S1566–0702(17):30338–30337
Cheung I, Vadas P (2015) A new disease cluster: mast cell activation syndrome, postural orthostatic tachycardia syndrome, and Ehlers-Danlos syndrome. J Allergy Clin Immunol. 135(2):AB65
Vengoechea J (2018) In reply to “Mast Cell Disorders in Ehlers-Danlos Syndrome”. Am J Med Genet. 176(1):250
Beighton P, Grahame R, Bird H (2012) The molecular basis of joint hypermobility. In: Hypermobility of joints. Springer, pp 27–47
Zweers MC, Hakim AJ, Grahame R, Schalkwijk J (2004) Joint hypermobility syndromes: the pathophysiologic role of tenascin-X gene defects. Arthritis Rheum. 50(9):2742–2749
Hirai S, Ohyane C, Kim Y, Lin S, Goto T, Takahashi N et al (2014) Involvement of mast cells in adipose tissue fibrosis. Am J Physiol Endocrinol Metab. 306(3):247
Hügle T (2014) Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 144:w13999
Bradding P, Pejler G (2018) The controversial role of mast cells in fibrosis. Immunol Rev. 282(1):198–231
Cairns JA, Walls AF (1997) Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 99(6):1313–1321
Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart F et al (2002) Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy. 32(2):237–246
Manel J, Befus D, Newhouse M, Bienenstock J, Gauldie J, McMaster U (1988) Effect of histamine on proliferation of normal human adult lung fibroblasts. Thorax. 43(7):552–558
Hatamochi A, Fujiwara K, Ueki H (1985) Effects of histamine on collagen synthesis by cultured fibroblasts derived from guinea pig skin. Arch Dermatol Res. 277(1):60–64
Russel JD, Russell SB, Trupin KM (1977) The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Cell Physiol. 93(3):389–393
Abe M, Kurosawa M, Ishikawa O, Miyachi Y (2000) Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol. 106(1 Pt 2):78
De Wandele I, Rombaut L, Leybaert L, Van de Borne P, De Backer T, Malfait F et al (2014) Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers–Danlos syndrome. Semin Arthritis Rheum. 44(1):93–100
Bonamichi-Santos R, Yoshimi-Kanamori K, Giavina-Bianchi P, Aun MV (2018) Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders. Immunol Allergy Clin N Am 38(3):497–504
Sabato V, Van De Vijver E, Hagendorens M, Vrelust I, Reyniers E, Fransen E et al (2014) Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol 134(6):1450.e3
Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M et al (2014) Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 133(5):1471–1474
Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y et al (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 48(12):1564–1569
Cardamone C, Parente R, Feo GD, Triggiani M (2016) Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett 178:10–14
Galli SJ, Tsai M (2010) Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol. 40(7):1843–1851
Suurmond J, Dorjée AL, Knol EF, Huizinga TWJ, Toes REM (2015) Differential TLR-induced cytokine production by human mast cells is amplified by FcɛRI triggering. Clin Exp Allergy. 45(4):788–796
Gallenga CE, Pandolfi F, Caraffa A, Kritas SK, Ronconi G, Toniato E et al (2019) Interleukin-1 family cytokines and mast cells: activation and inhibition. J Biol Regul Homeost Agents 33(1):1–6
Yu Y, Blokhuis BR, Garssen J, Redegeld FA (2016) Non-IgE mediated mast cell activation. Eur J Pharmacol 778:33–43
Jakate S, Demeo M, John R, Tobin M, Keshavarzian A (2006) Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 130(3):362–367
Hahn HP, Hornick JL (2007) Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol. 31(11):1669–1676
Sethi A, Jain D, Roland BC, Kinzel J, Gibson J, Schrader R et al (2015) Performing colonic mast cell counts in patients with chronic diarrhea of unknown etiology has limited diagnostic use. Arch Pathol Lab Med. 139(2):225–232
Doyle LA, Sepehr GJ, Hamilton MJ, Akin C, Castells MC, Hornick JL (2014) A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol. 38(6):832–843
Obrenovich MEM (2018) Leaky gut, leaky brain? Microorganisms 6(4)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kucharik, A.H., Chang, C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clinic Rev Allerg Immunol 58, 273–297 (2020). https://doi.org/10.1007/s12016-019-08755-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-019-08755-8